Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Безопасность комбинированной терапии СД типа 2: принцип внедорожника
Александров1 А.А., Ядрихинская1 М.Н., Кухаренко1 С.С., Шацкая1 О.А., Абдалкина2 Е.Н. Безопасность комбинированной терапии СД типа 2: принцип внедорожника. Consilium Medicum. 2013; 15 (5): 63–66.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Monami M, Luzzi C, Chiasserini V et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477–82.
2. Matsuo M, Ueda K, Ryder K, Ashcroft F. The sulphonylurea receptor: An ABCC transporter that acts as an ion channel regulator. In: Holland, IB ed. ABC proteins. Academic Press 2003; 551–76.
3. Proks P, Lippiat JD. Membrane ion channels and diabetes. Curr Pharm Des 2006; 12: 485–501.
4. Sukhodub A, Jovanovic S, Du Q et al. AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K+channels. J Cell Physiol 2007; 210: 224–36.
5. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999; 61: 337–62.
6. Shi NQ, Ye B, Makielski JC. Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol 2005; 39: 51–60.
7. Proks P, Lippiat JD. Membrane ion channels and diabetes. Curr Pharm Des 2006; 12: 485–501.
8. Aguilar-Bryan L, Nichols CG, Wechsler SW et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Sci 1995; 268: 423–6.
9. Michael A, Burke R. Kannan Mutharasan and Hossein Ardehali. The Sulfonylurea Receptor, an Atypical ATP-Binding Cassette Protein, and Its Regulation of the K ATP Channel. Circ Res 2008; 102: 164–76.
10. Ardehali H, O’Rourke B. Mitochondrial K (ATP) channels in cell survival and death. J Mol Cell Cardiol 2005; 39: 7–16.
11. Ardehali H, O’Rourke B. Mitochondrial K (ATP) channels in cell survival and death. J Mol Cell Cardiol 2005; 39: 7–16.
12. Proks P, Reimann F, Green N et al. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (Suppl. 3): S368–S376.
13. Quat U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004; 53 (Suppl. 3): S156–S164.
14. Ogawa K, Ikewaki K, Taniguchi I et al. Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. Int Heart J 2007; 48: 337–45.
15. Mocanu MM, Maddock HL, Baxter GF et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111–6.
16. Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006; 55: S16–S19.
17. Александров А.А. Сердечно-сосудистые осложнения и современный алгоритм сахароснижающей терапии: «Флорентийская перспектива». РМЖ (Эндокринология). 2010; 18 (14).
18. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74.
2. Matsuo M, Ueda K, Ryder K, Ashcroft F. The sulphonylurea receptor: An ABCC transporter that acts as an ion channel regulator. In: Holland, IB ed. ABC proteins. Academic Press 2003; 551–76.
3. Proks P, Lippiat JD. Membrane ion channels and diabetes. Curr Pharm Des 2006; 12: 485–501.
4. Sukhodub A, Jovanovic S, Du Q et al. AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K+channels. J Cell Physiol 2007; 210: 224–36.
5. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999; 61: 337–62.
6. Shi NQ, Ye B, Makielski JC. Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol 2005; 39: 51–60.
7. Proks P, Lippiat JD. Membrane ion channels and diabetes. Curr Pharm Des 2006; 12: 485–501.
8. Aguilar-Bryan L, Nichols CG, Wechsler SW et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Sci 1995; 268: 423–6.
9. Michael A, Burke R. Kannan Mutharasan and Hossein Ardehali. The Sulfonylurea Receptor, an Atypical ATP-Binding Cassette Protein, and Its Regulation of the K ATP Channel. Circ Res 2008; 102: 164–76.
10. Ardehali H, O’Rourke B. Mitochondrial K (ATP) channels in cell survival and death. J Mol Cell Cardiol 2005; 39: 7–16.
11. Ardehali H, O’Rourke B. Mitochondrial K (ATP) channels in cell survival and death. J Mol Cell Cardiol 2005; 39: 7–16.
12. Proks P, Reimann F, Green N et al. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (Suppl. 3): S368–S376.
13. Quat U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004; 53 (Suppl. 3): S156–S164.
14. Ogawa K, Ikewaki K, Taniguchi I et al. Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. Int Heart J 2007; 48: 337–45.
15. Mocanu MM, Maddock HL, Baxter GF et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111–6.
16. Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006; 55: S16–S19.
17. Александров А.А. Сердечно-сосудистые осложнения и современный алгоритм сахароснижающей терапии: «Флорентийская перспектива». РМЖ (Эндокринология). 2010; 18 (14).
18. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74.
Авторы
А.А.Александров1, М.Н.Ядрихинская1, С.С.Кухаренко1, О.А.Шацкая1, Е.Н.Абдалкина2
1. Кардиологическое отделение ФГБУ Эндокринологический научный центр Минздрава РФ, Москва;
2. Кафедра клинической медицины НОУ ВПО Самарский медицинский институт «РЕАВИЗ»
1. Кардиологическое отделение ФГБУ Эндокринологический научный центр Минздрава РФ, Москва;
2. Кафедра клинической медицины НОУ ВПО Самарский медицинский институт «РЕАВИЗ»
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.